THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...
Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug. The device, created in conjunction with ...
Cholesterol injections are just one of many medications that you can use along with other medical therapies to help lower your cholesterol. As with any therapy that you begin for the first time, you ...
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
Q. A renowned senior cardiologist in our area has been taking all his patients off statins and putting them on Repatha. He did this for my husband, and the results have been amazing. Within three ...
Amgen launched a direct-to-patient program Oct. 6 to offer its cholesterol medication Repatha at a reduced price. The AmgenNow program will provide Repatha for $239 per month — nearly 60% below the ...
Hosted on MSN
Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention
Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback